Exciting Diagnostic Innovations Alter the Healthcare Landscape - Seite 2

Izotropic Corporation (OTC: IZOZF) (CSE: IZO) announced last week breaking news that, "it has engaged StarFish Medical, Canada's largest medical device design, development and contract manufacturing company, to complete the final design and development of the Company's commercial breast CT model.

StarFish Medical Founder and CEO Scott Phillips commented on the collaboration:

"We have worked with numerous companies in the medical and breast imaging spaces. Izotropic has conducted significant technical, clinical and market-positioning efforts that provide a high level of confidence that the final product will meet patient, physician and marketplace requirements. We look forward to working with Izotropic on the development of the final commercial model of their breast CT imaging system and assisting them in design and manufacturing of the alpha, beta, and early stage production models of breast CT."

Four successive breast CT imaging systems (models) have been built at UC Davis Medical Centre in California by company Director and Principal Founder of breast CT, Dr. John Boone. Each of these systems had better clinical utility and image performance than its predecessor. The latest system has incorporated lessons learned from previous models and the incorporation of state-of-the-art subcomponents have improved clinical utility with exceptional high-resolution CT images of the breast. Izotropic holds the rights to this breast CT technology under its exclusive global License Agreement with The Regents of the University of California.

Dr. John McGraw, Consultant and Advisor with Izotropic spoke highly of the partnership:

"I have worked with StarFish Medical over the past 15 years, and have always been impressed with their expertise, and the engineering quality and timely delivery of their medical devices. Starfish is the best possible partner to help Izotropic accelerate the development of their breast CT imaging device and I am excited to continue our work together."

The relationship with StarFish Medical is an integral development. The Company looks forward to continuing to execute on its business plans to actualize dedicated breast CT and make meaningful advances for the earlier detection and treatment of breast cancers."

Earlier on April 15 Izotropic Corporation announced that, "the United States Patent and Trademark Office has issued U. S. Patent No. 10,548,549, entitled 'Measuring Breast Density Using Breast Computed Tomography' for a 20-year term, expiring in 2037. This patent covers the use of the Company's Breast CT Imaging System to measure breast density."